RxDoctor Payments Data

Mahmood Ahmed, MD

Internal Medicine · Griffin, GANPI 1902800899

Payments from drug & device makers

$1,181in general payments, 2019–2025

Across 72 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$188
  • Medtronic$143
  • Johnson & Johnson$128
  • Pfizer$128
  • Astellas Pharma US Inc$98
  • Novo Nordisk$78
  • plus $418 from 14 others

What the payments were for

  • Food & beverage$1,17099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,181 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$98,762
Medicare patients
259
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept13$110,542
OzempicSemaglutide60$83,601
EliquisApixaban80$69,800
JanuviaSitagliptin Phosphate70$67,814
JardianceEmpagliflozin48$46,912
TrulicityDulaglutide26$41,031
MounjaroTirzepatide31$32,379
FarxigaDapagliflozin Propanediol23$28,387
LinzessLinaclotide37$25,943
XareltoRivaroxaban19$22,107
MyrbetriqMirabegron23$18,308
RybelsusSemaglutide14$13,199
Spiriva RespimatTiotropium Bromide17$10,735
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen253$8,575
Colesevelam Hcl19$8,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$78$96,80074 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$12$79,81381 claims
PfizerEliquis, Premarin$128$72,37493 claims
MerckJanuvia$15$67,81470 claims
AbbVieLinzess, Synthroid$188$30,06893 claims
Johnson & JohnsonXarelto$128$22,10719 claims
Astellas Pharma US IncMyrbetriq$98$18,30823 claims
GSKBreo Ellipta$58$5,37213 claims
Sanofi-aventis U.S. LLCLantus$21$2,84520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Griffin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →